Advanced Lung Cancer
Conditions
Brief summary
This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer
Detailed description
The trial consist of Screening Period (30 days), Treatment Period (21\*n days), Safety Follow-up Period (90 days) and Survival follow-up. About 20 subjects are planned to be enrolled in the study.
Interventions
The WTX212A infusion is given every 21 days
The PD -1/PD-L1 monoclonal antibody is given every 21 days
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Westlake Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single-center, open-label, exploratory study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* The subject signs an informed consent form, understands this study, is willing to follow and has the ability to complete all experimental procedures; * Regardless of gender, aged 18 to 75 years old (including threshold); * Histologically or cytologically confirmed locally advanced (stage IIB/IIC) or metastatic (stage IV) non-small cell lung cancer (NSCLC) with disease progression or intolerance after treatment or extensive stage small cell Lung cancer (SCLC) * Patients with lung cancer who have been treated with at least 1 line system therapy or cannot currently receive standard therapy, and who have been treated with PD-1 or PD-L1 inhibitor antibody in the terminal line therapy regimen for ≥ 2 cycles; * ECOG ≤1 * Expected life ≥ 3 months； * Male participants, their spouses, and female participants of childbearing age should agree to use a medically recognized effective contraceptive method from the signing of the informed consent form until 3 months after the last administration;
Exclusion criteria
* People with other serious medical diseases, including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc., and people with uncontrollable or serious cardiovascular diseases, * Patients with clinical symptoms and the need for repeated drainage of pleural and ascitic fluids; * Previous or recent history of pulmonary fibrosis, severe lung function damage caused by pneumoconiosis, radiation pneumonia, and drug-related pneumonia; * There have been adverse events related to the use of IO drugs that require permanent cessation of IO treatment; * Known to have other malignant tumors, currently progressing or completing treatment at least once in the past 3 years. Exceptions include early tumors that have received radical treatment (carcinoma in situ or grade 1 tumor, non ulcerative primary melanoma with a depth of less than 1mm and no lymph nodes involved), skin basal cell carcinoma, skin squamous cell carcinoma, cervical carcinoma in situ, or breast carcinoma in situ that has received potential radical treatment; * Subjects with symptomatic central nervous system (CNS) metastasis confirmed by imaging or pathological examination and clinically unstable for at least 14 days prior to enrollment who require steroid treatment; * Having hereditary bleeding tendencies or coagulation disorders, or a history of thrombosis, hemolysis, or hemorrhagic diseases; * Received significant surgical treatment or obvious traumatic injury within 28 days prior to the start of research treatment;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the efficacy of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in the treatment of patients with IO- resistant advanced lung cancer. | 1 year | Overall Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the safety of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in the treatment of IO- resistant advanced lung cancer patients | 1 year | The incidence of adverse events (AE), treatment related adverse events (TRAE), and severe adverse events (SAE) during the treatment of WTX212A injection |
| To evaluate the pharmacokinetic ( PK ) characteristics of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with IO- resistant advanced lung cancer | 1 year | Peak Plasma Concentration (Cmax) |
| To evaluate the immunogenicity of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with IO -resistant advanced lung cancercheckpoint inhibitor resistance in advanced lung cancer patients | 1 year | Describe the percentage of anti-drug antibodies (ADA) produced by subjects at each time point after treatment |
Other
| Measure | Time frame | Description |
|---|---|---|
| To explore and evaluate WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in the treatment of IO- resistant advanced lung cancer before and after treatment, analysis of immune cell subpopulations | 1 year | Calculate the absolute values and percentages of immune cell subpopulations (absolute values and percentages of effector cells and immunosuppressive cells) before and after treatment of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in the treatment of IO -resistant advanced lung cancer. Immunomic analysis Variety |
| To explore and evaluate the changes in spleen size in patients with IO- resistant advanced lung cancer before and after treatment with WTX212A injection combined with PD -1/PD-L1 monoclonal antibody | 1 year | Changes in spleen size before and after treatmen |
| To evaluate the pharmacodynamics ( PD ) characteristics of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with IO- resistant advanced lung cancer | 1 year | The occupancy rate of PD-1 receptor on the surface of peripheral blood T cells in subjects after WTX212A infusion |
Countries
China
Contacts
Primary Contactpingli wang, phD
Outcome results
None listed